Showing 5451-5460 of 7902 results for "".
- FDA Approves Varithena to Treat Varicose Veinshttps://practicaldermatology.com/news/20131127-fda_approved_varithena_to_treat_varicose_veins/2459401/The FDA recently approved BTG plc's Varithena (polidocanol injectable foam) for the treatment of patients with incompetent veins and visible varicosities of the great saphenous vein (GSV) system. V
- Valeant Pharmaceuticals Announces Appointment of Dr. Ari Kellen to Executive Management Teamhttps://practicaldermatology.com/news/20131125-valeant_pharmaceuticals_announces_appointment_of_dr_ari_kellen_to_executive_management_team/2459405/Valeant Pharmaceuticals International, Inc. announced that Dr. Ari Kellen has been named to Valeant's Executive Management Team and will assume the role of Executive Vice President/Company Group Chairman, effective January 1,
- Caliber Imaging & Diagnostics Appoints Robert P. Fischmann VP of Operationshttps://practicaldermatology.com/news/20131125-caliber_imaging__diagnostics_appoints_robert_p_fischmann_vp_of_operations/2459406/Caliber Imaging & Diagnostics, formerly Lucid, Inc., has appointed Robert P. Fischmann to the role of Vice President of Operations, a newly created position. Mr. Fischmann's responsibilities at
- Lithera Announces Appointment of Dr. Lincoln Krochmal as Chief Medical Officerhttps://practicaldermatology.com/news/20131121-lithera_announces_appointment_of_dr_lincoln_krochmal_as_chief_medical_officer/2459407/Lincoln Krochmal, MD was recently appointed as Chief Medical Officer of Lithera, Inc. According to the company, this appointment reflects the company's continued growth as it prepares to enter la
- Investigational Melanoma Agent Improves Survival in Phase III Trialhttps://practicaldermatology.com/news/20131120-investigational_melanoma_agent_improves_survival_in_phase_iii_trial/2459408/Interim results from a pivotal Phase III trial show that Amgen's investigational agent talimogene laherpaepvec increased overall survival in patients with unresected stage IIIB, IIIC, or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF). The study found that median ov
- Actelion Launches Valchlor to Treat Stage IA and IB Mycosis Fungoides-type Cutaneous T-cell Lymphomahttps://practicaldermatology.com/news/20131119-actelion_launches_valchlor_to_treat_stage_ia_and_ib_mycosis_fungoides-type_cutaneous_t-cell_lymphoma/2459409/The FDA approved Actelion's Valchlor (mechlorethamine), the first and only FDA-approved topical formulation of mechlorethamine. Valchlor, a gel that is applied topically once a day, is an alkylating drug indicated to treat p
- Clear Clinic Acne Treatment Center Launches New Line, Online Componenthttps://practicaldermatology.com/news/20131119-clear_clinic_acne_treatment_center_launches_new_line_online_component/2459410/Clear Clinic Acne Treatment is launching a line of customized acne products along with an online program. Clear Clinic Online combines customized regimens from a new line of 19 acne products with guided care from a Personal Acne Coach, who will conduct consultations via video e-chat or telephone. Cl
- KLOX Technologies Announces European CE Mark Approval for Non-Invasive Acne Vulgaris Producthttps://practicaldermatology.com/news/20131119-klox_technologies_announces_european_ce_mark_approval_for_non-invasive_acne_vulgaris_product/2459411/KLOX Technologies Inc. announced that it has received CE mark approval in Europe for its topical photo-converter gel as a Class IIa Medical Device for the treatment of acne vulgaris, including all severities. The gel is part of the company's LumiCleanse System, a first-in-class,
- Antares Pharma Enters into Promotion and Marketing Agreement with LEO Pharma for Otrexuphttps://practicaldermatology.com/news/20131118-antares_pharma_enters_into_promotion_and_marketing_agreement_with_leo_pharma_for_otrexup/2459413/Antares Pharma, Inc. announced an exclusive agreement with LEO Pharma for the promotion and marketing of Otrexup (methotrexate) to dermatologists for symptomatic c
- Valeant's Antifungal Agent Luzu Wins FDA Approvalhttps://practicaldermatology.com/news/20131115-valeants_antifungal_luzu_wins_fda_approval/2459414/The FDA has approved Luzu® (luliconazole, Valeant) Cream, 1% for the topical treatment of athlete's foot (interdigital tinea pedis), jock itch (tinea cruris), and ringworm (tinea corporis), caused by the organisms Trichophyton rubrum and Epidermophyton floccosum, in patients 18 years of age and olde